-

Precision Medicine in Oncology Collaboration and Licensing Agreements Trends Analysis Report 2025: Biopharma Giants Enter 879 Precision Medicine Oncology Deals Since 2016 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016, including financial terms where available, with links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties.

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the world's leading biopharma companies. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.

The initial chapters of this report orient readers about precision medicine in oncology dealmaking. They cover an introduction to the report, trends in dealmaking since 2016, and featured leading deals ranked by headline value. Additionally, a detailed review of the top 25 most active companies in the field is provided, alongside insights into deals with publicly available contract documents, organized by specific technology types.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

2.1. Introduction

2.2. Precision medicine in oncology deals over the years

2.3. Most active precision medicine in oncology dealmakers

2.4. Precision medicine in oncology deals by deal type

2.5. Precision medicine in oncology deals by therapy area

2.6. Precision medicine in oncology deals by industry sector

2.7. Deal terms for precision medicine in oncology deals

2.7.1 Precision medicine in oncology deals headline values

2.7.2 Precision medicine in oncology deal upfront payments

2.7.3 Precision medicine in oncology deal milestone payments

2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

3.1. Introduction

3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

4.1. Introduction

4.2. Most active precision medicine in oncology dealmakers

4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

5.1. Introduction

5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

Deal directory

  • Deal directory - Precision medicine in oncology deals by company A-Z
  • Deal directory - Precision medicine in oncology deals by deal type
  • Deal directory - Precision medicine in oncology deals by therapy area
  • Deal type definitions

Companies Featured

  • 2cureX
  • 48Hour Discovery
  • A2 Biotherapeutics
  • AbbVie
  • Access to Comprehensive Genomic Profiling Coalition
  • Acerta Pharma
  • Acrivon Therapeutics
  • Adaptive Biotechnologies
  • ADC Therapeutics
  • Addario Lung Cancer Medical Institute
  • Affigen
  • Agilent Technologies
  • Agios Pharmaceuticals
  • Akoya Biosciences
  • Allarity Therapeutics
  • Alligator Bioscience
  • Ambry Genetics
  • AnHeart Therapeutics
  • Apollomics
  • Arcturus Therapeutics
  • Atreca
  • Biofidelity
  • Boehringer Ingelheim
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Cambridge Quantum Computing
  • Cancer Research UK
  • Caris Life Sciences
  • Celgene
  • Cleveland Clinic
  • Clovis Oncology
  • Columbia University
  • Compugen
  • Curis
  • Cytox Bioscience
  • Daiichi Sankyo
  • Dante Labs
  • Duke University
  • Flatiron Health
  • Foundation Medicine
  • Gilead Sciences
  • Guardant Health
  • HalioDx
  • IBM Watson Health
  • Illumina
  • Ionis Pharmaceuticals
  • Janssen Biotech
  • Jazz Pharmaceuticals
  • Juno Therapeutics
  • Kite Pharma

For more information about this report visit https://www.researchandmarkets.com/r/gt2dyt

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

2 Day Virtual MBA Strategic Thinking for Pharma and Biopharma Professionals Training Course (Feb 23rd - Feb 24th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "MBA Strategic Thinking for Pharma and Biopharma Professionals Training Course (Feb 23rd - Feb 24th, 2026)" training has been added to ResearchAndMarkets.com's offering. Working in the highly competitive pharmaceutical industry, with ever-increasing change and pressure, is probably one of the most challenging managerial roles of any industry today. This MBA strategic thinking workshop has been especially designed to help you transcend these challenges by training yo...

Automotive Refinish Coatings Market Set to Reach $19.67 Billion by 2032 - Expansion of Solid Color Refinish Portfolios With High-Solid Formulations to Lower Solvent Usage and Costs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Automotive Refinish Coatings Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The automotive refinish coatings market is evolving rapidly, propelled by changing customer demands, regulatory shifts, and technological innovation. This research equips industry leaders with comprehensive intelligence on emerging trends, competitive moves, and actionable strategies in this dynamic sector. Market Snapshot: Automotive Refinis...

Domain Name System (DNS) Firewall Market and Business Strategy Report 2025-2030: Rising Adoption of DNS Firewalls in E-Commerce Expands Addressable Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Domain Name System (DNS) Firewall - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Domain Name System (DNS) Firewall was valued at US$237.3 Million in 2024 and is projected to reach US$474.1 Million by 2030, growing at a CAGR of 12.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growt...
Back to Newsroom